Aktienanalyse zu Denali Therapeutics Inc (DNLI)DNLIDenali Therapeutics Inc

Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Denali Therapeutics Inc (DNLI) is a good buy right now due to its recent revenue growth of $3.6 million in Q2 2026, which exceeded expectations by $1.41 million, and a gross margin of 76.61%, indicating strong profitability potential. However, the main risk is the negative net income margin of -3539.21%, which reflects ongoing losses that investors should consider.

4 analysts cover DNLI: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.78.